This Small-Cap Healthcare Stock Is Up 300% in a Year and Is Quickly Gaining a Following

• NeurAxis (NRXS) specializes in neuromodulation therapies, targeting chronic abdominal pain in pediatric and adult patients.

• NRXS exhibits exceptional technical momentum with shares trading at new all-time highs.

• The stock is up more than 300% over the past 52 weeks and maintains a 100% “Buy” opinion from Barchart.

• Healthcare sector tailwinds support NRXS, yet prudent risk management is advised given volatility and speculative characteristics.

Today’s Featured Stock

Valued at $95.49 million, NeurAxis (NRXS) is a medical technology company focused on neuromodulation therapies to address chronic and debilitating conditions in children and adults.

The company’s primary product, IB-Stim, is a percutaneous electrical nerve field stimulation system designed for patients aged 8 and older, targeting functional abdominal pain associated with irritable bowel syndrome, functional dyspepsia, and associated nausea symptoms. Another notable product is the Rectal Expulsion Device, which aids in diagnosing evacuation disorders.

More News from Barchart

What I’m Watching

I found today’s Chart of the Day by using Barchart’s powerful screening functions to sort for stocks with the highest technical buy signals; superior current momentum in both strength and direction; and a Trend Seeker “buy” signal. I then used Barchart’s Flipcharts feature to review the charts for consistent price appreciation. NRXS checks those boxes. The Trend Seeker issued a new “Buy” signal on February 26. Since then, the stock has gained 54.3%.

Barchart Technical Indicators for NeurAxis

Editor’s Note: The technical indicators below are updated live during the session every 20 minutes and can therefore change each day as the market fluctuates. The indicator numbers shown below therefore may not match what you see live on the Barchart.com website when you read this report. These technical indicators form the Barchart Opinion on a particular stock.

NeurAxis scored an all-time high of $9.33 on May 5.

• NeurAxis has a Weighted Alpha of +346.77.

• NRXS has a 100% “Buy” opinion from Barchart.

• The stock has gained 300.91% over the past 52 weeks.

• NeurAxis has its Trend Seeker “Buy” signal intact.

• The stock recently traded at $8.70 with a 50-day moving average of $7.04.

• NRXS has made 4 new highs and gained 18.49% over the past month.

• Relative Strength Index (RSI) is at 67.66.

• There’s a technical support level around $8.19.

Don’t Forget the Fundamentals

• $95.49 million market capitalization.

• Analysts project revenue to grow 168.96% this year and another 115.63% next year.

• Earnings are estimated to increase 37.43% this year and an additional 94.55% next year.

Analyst and Investor Sentiment on NeurAxis

• The lone Wall Street analyst followed by Barchart gives the stock 1 “Strong Buy” opinion with a price target of $13.

• Value Line ranks the stock “Highest.”

• CFRA’s MarketScope rates the stock a “Sell.”

• Morningstar thinks the stock is 9% overvalued with a fair value of $7.59.

• 493 investors are following the stock on Seeking Alpha, which rates it a “Hold” and rates it the best healthcare stock.

• Short interest is 2.29% of the float with 2.20 days to cover the float.

The Bottom Line on NeurAxis

NeurAxis is a small-cap stock that is just getting noticed. The analyst following the stock is not looking for it to break-even until 2028. This is a very speculative stock.

Additional disclosure: The Barchart Chart of the Day highlights stocks that are experiencing exceptional current price appreciation. They are not intended to be buy recommendations as these stocks are extremely volatile and speculative. Should you decide to add one of these stocks to your investment portfolio it is highly suggested you follow a predetermined diversification and moving stop loss discipline that is consistent with your personal investment risk tolerance.

On the date of publication, Jim Van Meerten did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Barchart.com